{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T15:01:34Z","timestamp":1785164494095,"version":"3.55.0"},"reference-count":51,"publisher":"Akademiai Kiado Zrt.","issue":"4","license":[{"start":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T00:00:00Z","timestamp":1706400000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.akjournals.com"],"crossmark-restriction":true},"short-container-title":["OH"],"published-print":{"date-parts":[[2024,1,28]]},"abstract":"A mell\u00e9kvesek\u00e9reg-carcinoma ritka, rossz progn\u00f3zis\u00fa megbeteged\u00e9s. Az \u00e9rintett\n betegek k\u00f3rj\u00f3slat\u00e1t d\u00f6nt\u0151en meghat\u00e1rozza, hogy a betegs\u00e9g kor\u00e1n, m\u00e9g\n lokoregion\u00e1lis st\u00e1diumban ker\u00fclj\u00f6n felismer\u00e9sre, amikor a seb\u00e9szi\n tumorelt\u00e1vol\u00edt\u00e1ssal jelent\u0151sen n\u00f6velhet\u0151 a gy\u00f3gyul\u00e1s es\u00e9lye. A\n mell\u00e9kvese-daganatok dignit\u00e1s\u00e1nak meghat\u00e1roz\u00e1sa gyakran jelent kih\u00edv\u00e1st a\n preoperat\u00edv kivizsg\u00e1l\u00e1s sor\u00e1n, a diagn\u00f3zisalkot\u00e1st hagyom\u00e1nyos radiol\u00f3giai \u00e9s\n laborat\u00f3riumi vizsg\u00e1latok seg\u00edtik. \u00dajabban igen j\u00f3 diagnosztikai pontoss\u00e1got\n mutat\u00f3 biomarkerek is megismer\u00e9sre ker\u00fcltek, klinikai haszn\u00e1latuk a k\u00f6zelj\u00f6v\u0151ben\n v\u00e1rhat\u00f3. K\u00f6z\u00fcl\u00fck is kiemelkednek a g\u00e1z-, illetve folyad\u00e9kkromatogr\u00e1fi\u00e1n alapul\u00f3\n szteroidmetabolomikai vizsg\u00e1latok, valamint a miRNS-ek vizsg\u00e1lata. Ebben az\n \u00f6sszefoglal\u00f3ban bemutatjuk a mell\u00e9kvesek\u00e9reg-carcinoma azonos\u00edt\u00e1s\u00e1t seg\u00edt\u0151\n preoperat\u00edv klinikai \u00e9s posztoperat\u00edv patol\u00f3giai vizsg\u00e1l\u00f3m\u00f3dszereket. Orv Hetil.\n 2024; 165(4): 123\u2013131.<\/jats:p>","DOI":"10.1556\/650.2024.32958","type":"journal-article","created":{"date-parts":[[2024,1,28]],"date-time":"2024-01-28T11:19:30Z","timestamp":1706440770000},"page":"123-131","update-policy":"https:\/\/doi.org\/10.1556\/policypage.crossmark.crossref.2","source":"Crossref","is-referenced-by-count":1,"title":["A mell\u00e9kvesek\u00e9reg-carcinoma diagnosztik\u00e1ja"],"prefix":"10.1556","volume":"165","author":[{"given":"Judit","family":"T\u0151ke","sequence":"first","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika, Endo-ERN K\u00f6zpont Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikl\u00f3s","family":"T\u00f3th","sequence":"additional","affiliation":[{"name":"Semmelweis Egyetem, \u00c1ltal\u00e1nos Orvostudom\u00e1nyi Kar, Belgy\u00f3gy\u00e1szati \u00e9s Onkol\u00f3giai Klinika, Endo-ERN K\u00f6zpont Budapest, Kor\u00e1nyi S. u. 2\/a, 1083 Magyarorsz\u00e1g"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"425","reference":[{"key":"R1","doi-asserted-by":"crossref","unstructured":"Sherlock M, Scarsbrook A, Abbas A, et al. Adrenal incidentaloma.\n Endocr Rev. 2020; 41: 775\u2013820.","DOI":"10.1210\/endrev\/bnaa008"},{"key":"R2","doi-asserted-by":"crossref","unstructured":"Kerkhofs TM, Verhoeven RH, Van der Zwan JM, et al. Adrenocortical\n carcinoma: a population-based study on incidence and survival in the Netherlands\n since 1993. Eur J Cancer 2013; 49: 2579\u20132586.","DOI":"10.1016\/j.ejca.2013.02.034"},{"key":"R3","doi-asserted-by":"crossref","unstructured":"Sharma E, Dahal S, Sharma P, et al. The characteristics and trends\n in adrenocortical carcinoma. A United States population based study. J Clin Med\n Res. 2018; 10: 636\u2013640.","DOI":"10.14740\/jocmr3503w"},{"key":"R4","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Assie G, Baudin E, et al. Adrenocortical carcinomas and\n malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for\n diagnosis, treatment and follow-up. Ann Oncol. 2020; 31: 1476\u20131490. Erratum: Ann\n Oncol. 2023; 34: 631.","DOI":"10.1016\/j.annonc.2020.08.2099"},{"key":"R5","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Tsagarakis S, Terzolo M, et al. European Society of\n Endocrinology clinical practice guidelines on the management of adrenal\n incidentalomas, in collaboration with the European Network for the Study of\n Adrenal Tumors. Eur J Endocrinol. 2023; 189: G1\u2013G42.","DOI":"10.1093\/ejendo\/lvad066"},{"key":"R6","doi-asserted-by":"crossref","unstructured":"Glenn JA, Else T, Hughes DT, et al. Longitudinal patterns of\n recurrence in patients with adrenocortical carcinoma. Surgery 2019; 165:\n 186\u2013195.","DOI":"10.1016\/j.surg.2018.04.068"},{"key":"R7","doi-asserted-by":"crossref","unstructured":"Bancos I, Taylor AE, Chortis V, et al. Urine steroid metabolomics\n for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT\n study: a prospective test validation study. Lancet Diabetes Endocrinol. 2020; 8:\n 773\u2013781.","DOI":"10.1016\/S2213-8587(20)30218-7"},{"key":"R8","doi-asserted-by":"crossref","unstructured":"Schloetelburg W, Ebert I, Petritsch B, et al. Adrenal wash-out CT:\n moderate diagnostic value in distinguishing benign from malignant adrenal\n masses. Eur J Endocrinol. 2021; 186: 183\u2013193.","DOI":"10.1530\/EJE-21-0650"},{"key":"R9","doi-asserted-by":"crossref","unstructured":"I\u00f1iguez-Ariza NM, Kohlenberg JD, Delivanis DA, et al. Clinical,\n biochemical, and radiological characteristics of a single-center retrospective\n cohort of 705 large adrenal tumors. Mayo Clin Proc Innov Qual Outcomes 2018; 2:\n 30\u201339.","DOI":"10.1016\/j.mayocpiqo.2017.11.002"},{"key":"R10","doi-asserted-by":"crossref","unstructured":"Dinnes J, Bancos I, Ferrante di Ruffano L, et al. Management of\n endocrine disease: imaging for the diagnosis of malignancy in incidentally\n discovered adrenal masses: a systematic review and meta-analysis. Eur J\n Endocrinol. 2016; 175: R51\u2013R64.","DOI":"10.1530\/EJE-16-0461"},{"key":"R11","doi-asserted-by":"crossref","unstructured":"Lib\u00e9 R, Pais A, Violon F, et al. Positive correlation between\n 18F-FDG uptake and tumor-proliferating antigen Ki-67 expression\n in adrenocortical carcinomas. Clin Nucl Med. 2023; 48: 381\u2013386.","DOI":"10.1097\/RLU.0000000000004593"},{"key":"R12","doi-asserted-by":"crossref","unstructured":"Yalon T, Yalon M, Assaf D, et al. Differentiating between\n adrenocortical carcinoma and lipid-poor cortical adenoma: a novel\n cross-sectional imaging-based score. Surgery 2023; 173: 35\u201342.","DOI":"10.1016\/j.surg.2022.07.029"},{"key":"R13","doi-asserted-by":"crossref","unstructured":"Singh Y, Kelm ZS, Faghani S, et al. Deep learning approach for\n differentiating indeterminate adrenal masses using CT imaging. Abdom Radiol (NY)\n 2023; 48: 3189\u20133194.","DOI":"10.1007\/s00261-023-03988-w"},{"key":"R14","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Johanssen S, Quinkler M, et al. Limited prognostic\n value of the 2004 International Union Against Cancer staging classification for\n adrenocortical carcinoma: proposal for a revised TNM classification. Cancer\n 2009; 115: 243\u2013250.","DOI":"10.1002\/cncr.24030"},{"key":"R15","doi-asserted-by":"crossref","unstructured":"Elhassan YS, Altieri B, Berhane S, et al. S-GRAS score for\n prognostic classification of adrenocortical carcinoma: an international,\n multicenter ENSAT study. Eur J Endocrinol. 2022; 186: 25\u201336.","DOI":"10.1530\/EJE-21-0510"},{"key":"R16","doi-asserted-by":"crossref","unstructured":"T\u0151ke J, Uhlyarik A, Lohinszky J, et al. Prognostic factors and\n mitotane treatment of adrenocortical cancer. Two decades of experience from an\n institutional case series. Front Endocrinol (Lausanne) 2022; 13:\n 952418.","DOI":"10.3389\/fendo.2022.952418"},{"key":"R17","doi-asserted-by":"crossref","unstructured":"Lippert J, Altieri B, Morrison B, et al. Prognostic role of targeted\n methylation analysis in paraffin-embedded samples of adrenocortical carcinoma. J\n Clin Endocrinol Metab. 2022; 107: 2892\u20132899.","DOI":"10.1210\/clinem\/dgac470"},{"key":"R18","doi-asserted-by":"crossref","unstructured":"Ayala-Ramirez M, Jasim S, Feng L, et al. Adrenocortical carcinoma:\n clinical outcomes and prognosis of 330 patients at a tertiary care center. Eur J\n Endocrinol. 2013; 169: 891\u2013899.","DOI":"10.1530\/EJE-13-0519"},{"key":"R19","doi-asserted-by":"crossref","unstructured":"Else T, Williams AR, Sabolch A, et al. Adjuvant therapies and\n patient and tumor characteristics associated with survival of adult patients\n with adrenocortical carcinoma. J Clin Endocrinol Metab. 2014; 99:\n 455\u2013461.","DOI":"10.1210\/jc.2013-2856"},{"key":"R20","doi-asserted-by":"crossref","unstructured":"Baechle JJ, Marincola Smith P, Sol\u00f3rzano CC, et al. Cumulative GRAS\n score as a predictor of survival after resection for adrenocortical carcinoma:\n analysis from the U.S. adrenocortical carcinoma database. Ann Surg Oncol. 2021;\n 28: 6551\u20136561.","DOI":"10.1245\/s10434-020-09562-8"},{"key":"R21","doi-asserted-by":"crossref","unstructured":"Fassnacht M, Dekkers OM, Else T, et al. European Society of\n Endocrinology Clinical Practice Guidelines on the management of adrenocortical\n carcinoma in adults, in collaboration with the European Network for the Study of\n Adrenal Tumors. Eur J Endocrinol. 2018; 179: G1\u2013G46.","DOI":"10.1530\/EJE-18-0608"},{"key":"R22","doi-asserted-by":"crossref","unstructured":"Kiseljak-Vassiliades K, Bancos I, Hamrahian A, et al. American\n Association of Clinical Endocrinology Disease State Clinical Review on the\n evaluation and management of adrenocortical carcinoma in an adult: a practical\n approach. Endocr Pract. 2020; 26: 1366\u20131383.","DOI":"10.4158\/DSCR-2020-0567"},{"key":"R23","doi-asserted-by":"crossref","unstructured":"Arlt W, Biehl M, Taylor AE, et al. Urine steroid metabolomics as a\n biomarker tool for detecting malignancy in adrenal tumors. J Clin Endocrinol\n Metab. 2011; 96: 3775\u20133784.","DOI":"10.1210\/jc.2011-1565"},{"key":"R24","doi-asserted-by":"crossref","unstructured":"Kerkhofs TM, Kerstens MN, Kema IP, et al. Diagnostic value of\n urinary steroid profiling in the evaluation of adrenal tumors. Horm Cancer 2015;\n 6: 168\u2013175.","DOI":"10.1007\/s12672-015-0224-3"},{"key":"R25","doi-asserted-by":"crossref","unstructured":"Velikanova LI, Shafigullina ZR, Lisitsin AA, et al. Different types\n of urinary steroid profiling obtained by high-performance liquid chromatography\n and gas chromatography-mass spectrometry in patients with adrenocortical\n carcinoma. Horm Cancer 2016; 7: 327\u2013335.","DOI":"10.1007\/s12672-016-0267-0"},{"key":"R26","doi-asserted-by":"crossref","unstructured":"Vogg N, M\u00fcller T, Floren A, et al. Simplified urinary steroid\n profiling by LC-MS as diagnostic tool for malignancy in adrenocortical tumors.\n Clin Chim Acta 2023; 543: 117301.","DOI":"10.1016\/j.cca.2023.117301"},{"key":"R27","doi-asserted-by":"crossref","unstructured":"Berke K, Constantinescu G, Masjkur J, et al. Plasma steroid\n profiling in patients with adrenal incidentaloma. J Clin Endocrinol Metab. 2022;\n 107: e1181\u2013e1192.","DOI":"10.1210\/clinem\/dgab751"},{"key":"R28","doi-asserted-by":"crossref","unstructured":"Schweitzer S, Kunz M, Kurlbaum M, et al. Plasma steroid metabolome\n profiling for the diagnosis of adrenocortical carcinoma. Eur J Endocrinol. 2019;\n 180: 117\u2013125.","DOI":"10.1530\/EJE-18-0782"},{"key":"R29","doi-asserted-by":"crossref","unstructured":"Gambella A, Volante M, Papotti M. Histopathologic features of\n adrenal cortical carcinoma. Adv Anat Pathol. 2023; 30: 34\u201346.","DOI":"10.1097\/PAP.0000000000000363"},{"key":"R30","doi-asserted-by":"crossref","unstructured":"Weiss LM. Comparative histologic study of 43 metastasizing and\n nonmetastasizing adrenocortical tumors. Am J Surg Pathol. 1984; 8:\n 163\u2013169.","DOI":"10.1097\/00000478-198403000-00001"},{"key":"R31","doi-asserted-by":"crossref","unstructured":"Aubert S, Wacrenier A, Leroy X, et al. Weiss system revisited: a\n clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am\n J Surg Pathol. 2002; 26: 1612\u20131619.","DOI":"10.1097\/00000478-200212000-00009"},{"key":"R32","doi-asserted-by":"crossref","unstructured":"Volante M, Bollito E, Sperone P, et al. Clinicopathological study of\n a series of 92 adrenocortical carcinomas: from a proposal of simplified\n diagnostic algorithm to prognostic stratification. Histopathology 2009; 55:\n 535\u2013543.","DOI":"10.1111\/j.1365-2559.2009.03423.x"},{"key":"R33","doi-asserted-by":"crossref","unstructured":"Pennanen M, Heiskanen I, Sane T, et al. Helsinki score \u2013 a novel\n model for prediction of metastases in adrenocortical carcinomas. Hum Pathol.\n 2015; 46: 404\u2013410.","DOI":"10.1016\/j.humpath.2014.11.015"},{"key":"R34","doi-asserted-by":"crossref","unstructured":"Duregon E, Cappellesso R, Maffeis V, et al. Validation of the\n prognostic role of the \u201cHelsinki Score\u201d in 225 cases of adrenocortical\n carcinoma. Hum Pathol. 2017; 62: 1\u20137.","DOI":"10.1016\/j.humpath.2016.09.035"},{"key":"R35","doi-asserted-by":"crossref","unstructured":"Bukovszky B, G\u00e1cs Z, Jen\u0151v\u00e1ri Z, et al. Pediatric adrenocortical\n adenoma presenting with Cushing\u2019s syndrome. [Cushing-szindr\u00f3m\u00e1t okoz\u00f3\n gyermekkori mell\u00e9kvesek\u00e9reg-adenoma.] Orv Hetil. 2022; 163: 407\u2013412.\n [Hungarian]","DOI":"10.1556\/650.2022.32358"},{"key":"R36","doi-asserted-by":"crossref","unstructured":"Riedmeier M, Decarolis B, Haubitz I, et al. Adrenocortical carcinoma\n in childhood: a systematic review. Cancers (Basel) 2021; 13.\n 5266.","DOI":"10.3390\/cancers13215266"},{"key":"R37","doi-asserted-by":"crossref","unstructured":"Wieneke JA, Thompson LD, Heffess CS. Adrenal cortical neoplasms in\n the pediatric population: a clinicopathologic and immunophenotypic analysis of\n 83 patients. Am J Surg Pathol. 2003; 27: 867\u2013881.","DOI":"10.1097\/00000478-200307000-00001"},{"key":"R38","doi-asserted-by":"crossref","unstructured":"Lib\u00e9 R, Borget I, Ronchi CL, et al. Prognostic factors in stage\n III\u2013IV adrenocortical carcinomas (ACC): an European Network for the Study of\n Adrenal Tumor (ENSAT) study. Ann Oncol. 2015; 26: 2119\u20132125.","DOI":"10.1093\/annonc\/mdv329"},{"key":"R39","doi-asserted-by":"crossref","unstructured":"Mizdrak M, Ti\u010dinovi\u0107 Kurir T, Bo\u017ei\u0107 J. The role of biomarkers in\n adrenocortical carcinoma: a review of current evidence and future perspectives.\n Biomedicines 2021; 9: 174.","DOI":"10.3390\/biomedicines9020174"},{"key":"R40","doi-asserted-by":"crossref","unstructured":"Creemers SG, Feelders RA, Valdes N, et al. The IGF2 methylation\n score for adrenocortical cancer: an ENSAT validation study. Endocr Relat Cancer\n 2020; 27: 541\u2013550.","DOI":"10.1530\/ERC-19-0378"},{"key":"R41","doi-asserted-by":"crossref","unstructured":"Steenaard RV, Feelders RA, Dogan F, et al. The role of the\n IGF2 methylation score in diagnosing adrenocortical tumors\n with unclear malignant potential-feasibility of formalin-fixed paraffin-embedded\n tissue. Biomedicines 2023; 11: 2013.","DOI":"10.3390\/biomedicines11072013"},{"key":"R42","doi-asserted-by":"crossref","unstructured":"Kamilaris CD, Hannah-Shmouni F, Stratakis CA. Adrenocortical\n tumorigenesis: lessons from genetics. Best Pract Res Clin Endocrinol Metab.\n 2020; 34: 101428.","DOI":"10.1016\/j.beem.2020.101428"},{"key":"R43","doi-asserted-by":"crossref","unstructured":"V\u00e9kony B, Igaz P. The genetic background of primary aldosteronism.\n [A primer hyperaldosteronismus genetik\u00e1ja.] Orv Hetil. 2023; 164: 332\u2013338.\n [Hungarian]","DOI":"10.1556\/650.2023.32730"},{"key":"R44","doi-asserted-by":"crossref","unstructured":"Turai PI, Herold Z, Nyir\u0151 G, et al. Tissue miRNA combinations for\n the differential diagnosis of adrenocortical carcinoma and adenoma established\n by artificial intelligence. Cancers (Basel) 2022; 14: 895.","DOI":"10.3390\/cancers14040895"},{"key":"R45","doi-asserted-by":"crossref","unstructured":"Turai PI, Nyir\u0151 G, Borka K, et al. Exploratory circular RNA\n profiling in adrenocortical tumors. Cancers (Basel) 2022; 14:\n 4313.","DOI":"10.3390\/cancers14174313"},{"key":"R46","doi-asserted-by":"crossref","unstructured":"Di Dalmazi G, Altieri B, Scholz C, et al. RNA sequencing and somatic\n mutation status of adrenocortical tumors: novel pathogenetic insights. J Clin\n Endocrinol Metab. 2020; 105: dgaa616.","DOI":"10.1210\/clinem\/dgaa616"},{"key":"R47","doi-asserted-by":"crossref","unstructured":"Decmann \u00c1, Perge P, Nagy Z, et al. Circulating microRNAs in the\n diagnostics of endocrine neoplasms. [Kering\u0151 mikroRNS-ek az endokrin daganatok\n diagnosztik\u00e1j\u00e1ban.] Orv Hetil. 2017; 158: 483\u2013490. [Hungarian]","DOI":"10.1556\/650.2017.30708"},{"key":"R48","doi-asserted-by":"crossref","unstructured":"Nagy Z, Decmann \u00c1, Perge P, et al. Pathogenic and diagnostic roles\n of microRNAs in adrenocortical tumours. [A mikro-RNS-ek patogenetikai \u00e9s\n diagnosztikai szerepe mell\u00e9kvesek\u00e9reg-carcinom\u00e1ban.] Orv Hetil. 2018; 159:\n 245\u2013251. [Hungarian]","DOI":"10.1556\/650.2018.30919"},{"key":"R49","doi-asserted-by":"crossref","unstructured":"Koperski \u0141, Kotlarek M, \u015awierniak M, et al. Next-generation\n sequencing reveals microRNA markers of adrenocortical tumors malignancy.\n Oncotarget 2017; 8: 49191\u201349200.","DOI":"10.18632\/oncotarget.16788"},{"key":"R50","doi-asserted-by":"crossref","unstructured":"Decmann A, Bancos I, Khanna A, et al. Comparison of plasma and\n urinary microRNA-483-5p for the diagnosis of adrenocortical malignancy. J\n Biotechnol. 2019; 297: 49\u201353.","DOI":"10.1016\/j.jbiotec.2019.03.017"},{"key":"R51","doi-asserted-by":"crossref","unstructured":"Chabre O, Lib\u00e9 R, Assie G, et al. Serum miR-483-5p and miR-195 are\n predictive of recurrence risk in adrenocortical cancer patients. Endocr Relat\n Cancer 2013; 20: 579\u2013594.","DOI":"10.1530\/ERC-13-0051"}],"container-title":["Orvosi Hetilap"],"original-title":[],"link":[{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/4\/article-p123.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/4\/article-p123.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/www.akjournals.com\/downloadpdf\/journals\/650\/165\/4\/article-p123.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T14:29:13Z","timestamp":1785162553000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.akjournals.com\/view\/journals\/650\/165\/4\/article-p123.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,28]]},"references-count":51,"journal-issue":{"issue":"4"},"URL":"https:\/\/doi.org\/10.1556\/650.2024.32958","relation":{},"ISSN":["0030-6002","1788-6120"],"issn-type":[{"value":"0030-6002","type":"print"},{"value":"1788-6120","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,28]]}}}